Interdependence of magnetism and superconductivity in the borocarbide TmNi2B2C

We have discovered a new antiferromagnetic phase in TmNi2B2C by neutron diffraction. The ordering vector is Q_A = (0.48,0,0) and the phase appears above a critical in-plane magnetic field of 0.9 T. The field was applied in order to test the assumption that the zero-field magnetic structure at Q_F = (0.094,0.094,0) would change into a c-axis ferromagnet if superconductivity were destroyed. We present theoretical calculations which show that two effects are important: A suppression of the ferromagnetic component of the RKKY exchange interaction in the superconducting phase, and a reduction of the superconducting condensation energy due to the periodic modulation of the moments at the wave vector Q_A

Deep far infrared ISOPHOT survey in "Selected Area 57", I. Observations and source counts

We present here the results of a deep survey in a 0.4 sq.deg. blank field in Selected Area 57 conducted with the ISOPHOT instrument aboard ESAs Infrared Space Observatory (ISO) at both 60 um and 90 um. The resulting sky maps have a spatial resolution of 15 x 23 sq.arcsec. per pixel which is much higher than the 90 x 90 sq.arcsec. pixels of the IRAS All Sky Survey. We describe the main instrumental effects encountered in our data, outline our data reduction and analysis scheme and present astrometry and photometry of the detected point sources. With a formal signal to noise ratio of 6.75 we have source detection limits of 90 mJy at 60 um and 50 mJy at 90 um. To these limits we find cumulated number densities of 5+-3.5 per sq.deg. at 60 um and 14.8+-5.0 per sq.deg.at 90 um. These number densities of sources are found to be lower than previously reported results from ISO but the data do not allow us to discriminate between no-evolution scenarios and various evolutionary models.Comment: 15 pages, 11 figures, accepted by Astronomy & Astrophysic

Disseminated lung cancer presenting as a rectal mass

Primary lung cancer is the leading cause of cancer-related deaths globally, and approximately 50% had metastatic disease at the time of diagnosis. A rectal mass and unintended weight loss are common manifestations of rectal cancer. Our case presented with a rectal mass, but workup revealed a metastatic lesion from lung cancer. Lung cancer metastases to the lower gastrointestinal tract imply reduced survival compared with the already poor mean survival of stage IV lung cancer. Despite relevant therapy, the patient died 5 months after referral

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab : A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians' choice of treatment. COBRA (NCT04533737) was a randomized (1:1), blinded (patient and assessor), 28-week, active-comparator trial conducted in Europe from December 2020 to December 2022. The objective was to compare the efficacy and safety of brodalumab versus guselkumab in adults with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab. Patients received either brodalumab 210 mg or guselkumab 100 mg. The primary [having Psoriasis Area and Severity Index (PASI)-100 response at week 16] and key secondary (time to PASI-100 response) endpoints were tested in a fixed sequence. Due to delays and enrollment challenges, recruitment was terminated with 113 patients enrolled of 240 planned. The proportion of patients having PASI-100 at week 16 for brodalumab was 53.4% compared with 35.9% for guselkumab [odds ratio (OR) 2.05; 95% confidence interval (CI) 0.95, 4.44; p = 0.069]. As this was not statistically significant, the hierarchical testing procedure was stopped. All other secondary PASI endpoints had nominal p -values below 0.05 in favor of brodalumab. In the time to PASI response analyses, brodalumab separated from guselkumab in estimated cumulative incidence of patients achieving a response from week 2 onward, suggesting fast onset of action with brodalumab. Quality of life measures improved in both treatment groups. The safety findings were consistent with the known safety profiles. Brodalumab showed a tendency toward better and earlier effect than guselkumab in patients who had failed ustekinumab. Thus, this trial provides important information in assisting physicians in their choice of therapy for patients who have failed their prior anti-interleukin (IL)-12/23 treatment